Glycopyrrolate Contraindication in Myasthenia Gravis

Mechanism of Harm and Clinical Consequences

• Myasthenia gravis is characterized by autoimmune destruction of acetylcholine receptors at the motor endplate, resulting in impaired neuromuscular transmission, and is treated with acetylcholinesterase inhibitors that increase acetylcholine availability at the neuromuscular junction 1
• Patients with myasthenia gravis who receive glycopyrrolate face increased risk of respiratory compromise, as respiratory muscle weakness represents the most severe manifestation of MG 2

Alternative Approaches and Monitoring

• The American College of Physicians and other medical societies recommend avoiding all anticholinergic medications when possible in MG patients, and if secretion management is needed in non-palliative settings, consulting neurology before initiating any anticholinergic agent 2, 5
• Monitoring respiratory function closely is crucial if any questionable medication must be used in patients with myasthenia gravis 3, 4